A5003790985- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Advanced Radiotherapy Techniques
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Meningioma and schwannoma management
- Management of metastatic bone disease
- Radiation Therapy and Dosimetry
- Prostate Cancer Treatment and Research
- Pituitary Gland Disorders and Treatments
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- COVID-19 and healthcare impacts
- Breast Cancer Treatment Studies
- Adrenal and Paraganglionic Tumors
- Bone and Joint Diseases
- Cancer Treatment and Pharmacology
- Prostate Cancer Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Spinal Fractures and Fixation Techniques
- Hepatitis B Virus Studies
Dana-Farber Cancer Institute
2016-2025
Dana-Farber Brigham Cancer Center
2016-2025
Brigham and Women's Hospital
2014-2025
Harvard University
2015-2024
Foundation Medicine (United States)
2021
Boston Foundation
2021
Center for Neuro-Oncology
2017
Accelerate Brain Cancer Cure
2017
Massachusetts General Hospital
2014-2017
Boston Children's Hospital
2016
Abstract Background. High-grade gliomas with mutations in the isocitrate dehydrogenase (IDH) gene family confer longer overall survival relative to their IDH-wild-type counterparts. Accurate determination of IDH genotype preoperatively may have both prognostic and diagnostic value. The current study used a machine-learning algorithm generate model predictive high-grade based on clinical variables multimodal features extracted from conventional MRI. Methods. Preoperative MRIs were obtained...
The worldwide burden of sickle cell disease is enormous, with over 200,000 infants born the each year in Africa alone. Induction fetal hemoglobin a validated strategy to improve symptoms and complications this disease. development targeted therapies has been limited by absence discrete druggable targets. We developed unique bead-based for identification inducers transcripts primary human erythroid cells. A small-molecule screen bioactive compounds identified remarkable class-associated...
Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to development leukemia. Patients interstitial deletion Chromosome 5q have high rate response lenalidomide, but most MDS lack this deletion. Approximately 25% without deletions also benefit from lenalidomide therapy, in these cannot be predicted any currently available diagnostic...
We evaluated the efficacy and safety of risk-adapted, proton-based stereotactic body radiation therapy (SBRT) for liver metastases from solid tumors.This single-arm phase II single institutional study (NCT01239381) included patients with limited extrahepatic disease, 800 mL or greater uninvolved liver, no cirrhosis Child-Pugh A, who had received SBRT to one four tumors. Treatment comprised 30 50 Gray equivalent (GyE) in five fractions based on effective volume irradiated. Sample size was...
The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human 2 CC-115 deoxyribonucleic acid-dependent protein kinase/mammalian target rapamycin inhibitor]) were...
Stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) for prostate cancer allows MR-based contouring, real-time MR motion management, and daily plan adaptation. The clinical dosimetric benefits associated with SMART remain largely unknown.
<p>Supplementary Figure 7. Cellular Neighborhood Analyses. Comparison of annotated cellular neighborhoods in pre- and post-treatment tumor samples via CODEX (color code as 4).</p>
<p>Supplementary Figure 3. Digital quantification from immunohistochemistry. immunohistochemistry for T cell subsets and marker analysis paired tumor samples five patients enrolled to cohort A.</p>
<p>Supplementary Figure 6. Cell-cell interaction analyses. comparison in pre- and post-treatment tumor samples using CODEX for patient #5. (A) All significant interacting cell types shown the entire analyzed region as annotated. (B) Example images of – interactions showing CD163+ macrophages with GZMB+ CD8 T cells, CD4 CD68+ cells. The plus sign indicates that were close proximity at a one-cell distance (20 pixels).</p>
<p>Supplementary Figure 2. Patient enrollment, treatment and disposition per cohort.</p>
<p>Supplementary Figure 4. CODEX analysis of tumor PD-L1 expression patterns. (A) was detected in NCAM-1+ cells surrounding by hypoxia region as CA9 staining. (B) also observed GFAP+ surrounded the vicinity apoptotic (cleaved caspase-3 detection).</p>
<div>AbstractPurpose:<p>Radiotherapy may enhance antitumor immune responses by several mechanisms, including induction of immunogenic cell death. We performed a phase 2 study pembrolizumab with re-irradiation in patients recurrent glioblastoma.</p>Patients and Methods:<p>Sixty glioblastoma received alone (cohort A, bevacizumab-naïve; <i>n</i> = 30) or bevacizumab continuation B, 30). Dual primary endpoints, the overall response rate survival (OS) at either...
<p>Supplementary Figure 1. CODEX panel and experimental procedure. used to identify tumor cell subpopulations, immune populations key cellular markers. (B) Experimental workflow for 5 pre- post-treatment FFPE samples. ROIs were selected multiplexed imaging downstream analysis. (C) U Map clusters show major populations. Immune showed similar clustering in post- treatment samples.</p>
<p>Supplementary Figure 5. Cell Density Analyses. Comparison of defined cell populations in pre- and post-treatment tumor specimens via CODEX. (A) Each indicated type is shown as a percentage total cells each post-tumor specimen for all five patients. (B) density T subpopulations preand patient. CD4 are different shades blue; CD8 red. was determined by count per microm2. increased substantially patient #5. (C) changes paired posttreatment samples. Patient #5 highlighted with blue...
Patients with NSCLC and brain metastases have a poor prognosis. Combining brain-directed radiation therapy (RT) immune checkpoint inhibitors (ICIs) may be synergistic. Nevertheless, predictors of response toxicity are lacking. This retrospective study conducted at Dana-Farber Brigham Cancer Center from 2015 to 2023 included patients non-EGFR non-ALK-altered newly diagnosed starting ICI within 90 days RT. We assessed all-cause mortality, systemic neurologic death, intracranial progression the...